Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41

Microbiology and Immunology

Volumn 44, Issue 11, 2000, Pages 923-929

  Matsuda, Shunji ^a   Noda, Masahiro ^b  

^a NATIONAL HOSPITAL ORGANIZATION KURE MEDICAL CENTER AND CHUGOKU CANCER CENTER   (Japan)

^b Hiroshima Prefectural Institute of Public Health and Environment   (Japan)

Author keywords

gp120; gp41; HIV 1; IgA; Plasma; Saliva

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A ANTIBODY;

ANALYTIC METHOD; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MUCOSAL IMMUNITY; PLASMA; SALIVA; VACCINE PRODUCTION; VIRUS NEUTRALIZATION;

EID: 0034529907     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2000.tb02584.x     Document Type: Article

References (23)

1. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM
2. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate
3. Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals
4. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
5. Serum IgA immune response to individual rotavirus polypeptides in young children with rotavirus infection
6. Part II-B Maps of MAb locations plotted by protein
7. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons Masking by IgG
8. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
9. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
10. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
11. Chemokine receptor-usage of clinical HIV-1 isolates obtained from patients with HIV-1 infection in late clinical stages using PHA-blast
12. Mucosal immune system of the human genital tract
13. Mucosal immunoglobulins
14. An infectious DNA clone of HIV type 1 subtype C
15. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients
16. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
17. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
18. Antibody neutralization of HIV-1 and the potential for vaccine design
19. Salivary sIgA response in HIV-1 infection
20. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glyco-protein 120
21. Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4
22. The antigenic structure of the HIV gp120 envelope glycoprotein
23. The HIV-1 envelope glycoproteins fusogens, antigens, and immunogens